Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin Against Pseudomonas Aeruginosa in a Dynamic in Vitro Hollow-Fiber Infection Model

Given that aminoglycosides, such as amikacin, may be used for multidrug-resistant Pseudomonas aeruginosa infections, optimization of therapy is paramount for improved treatment outcomes. This study aims to investigate the pharmacodynamics of different simulated intravenous amikacin doses on susceptible P. aeruginosa to inform ventilator-associated pneumonia (VAP) and sepsis treatment choices. A hollow-fiber infection model with two P. aeruginosa isolates (MICs of 2 and 8 mg/liter) with an initial inoculum of ∼10 8 CFU/ml was used to test different amikacin dosing regimens.